<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161001</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1451301</org_study_id>
    <nct_id>NCT04161001</nct_id>
  </id_info>
  <brief_title>Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  the change of sitSBP based on baseline between Treatment arm and control 1 arm [ Time
           Frame: 8 weeks ]

        -  the change of LDL-C based on baseline between Treatment arm and control2 arm [ Time
           Frame: 8 weeks ]
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2019</start_date>
  <completion_date type="Anticipated">February 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of MSSBP based on baseline between Treatment arm and control 1 arm</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of LDL-C based on baseline between Treatment arm and control2 arm</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Hypertension, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan, Rosuvastatin, Ezetimibe</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>co-administration of Olmesartan and Rosuvastatin, Ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodpine, Olmesartan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>co-administration of Olmesartan, Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)</intervention_name>
    <description>co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)</description>
    <arm_group_label>Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)</intervention_name>
    <description>co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)</description>
    <arm_group_label>Olmesartan, Rosuvastatin, Ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Olmesartan 10/40mg (Combination drug)</intervention_name>
    <description>co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)</description>
    <arm_group_label>Amlodpine, Olmesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 to 80 years

          -  patients with hypertension and hyperlipidemias

        Exclusion Criteria:

          -  orthostatic hypotension

          -  History of ventricular tachycardia, atrial fibrillation

          -  uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daewoong clinical</last_name>
    <phone>+82-2-550-8800</phone>
    <phone_ext>8800</phone_ext>
    <email>shj@daewoong.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyunju Shin</last_name>
    <email>shj@daewoong.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongwon Ha</last_name>
      <phone>82-02-2228-8448</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Amlodipine Besylate, Olmesartan Medoxomil Drug Combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

